Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper authored by Furong Kou et al. in the ASCO Journal:
“HER2-Low in mBRCA1/2 TNBC:
– mBRCA1: 38.8% were HER2-low
- RFS: 90.3% vs 75.1%
- DRFS: 92.4% vs 76.5%
- OS: 94.6% vs 77.4%
Higher HRD in HER2-low.
– mBRCA2
No survival difference by HER2 status.“
Authors: Furong Kou et al.
The complete article is available on ASCO Journal.
More posts featuring Sergio Cifuentes on OncoDaily.
